Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

396 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Consequences of Discontinuing a 4/6 Cyclin D-Dependent Kinase Inhibitor During Endocrine Treatment in Hormone-Sensitive Metastatic Breast Cancer Patients in the Context of the COVID-19 Outbreak.
Martin S, Pflumio C, Trensz P, Schaff-Wendling F, Weindling MK, Fischbach C, Pierard L, Limacher JM, Nader R, Velten M, Petit T. Martin S, et al. Among authors: velten m. Clin Breast Cancer. 2023 Jan;23(1):32-37. doi: 10.1016/j.clbc.2022.10.006. Epub 2022 Oct 13. Clin Breast Cancer. 2023. PMID: 36414498 Free PMC article.
Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial.
Borel C, Sun XS, Coutte A, Bera G, Sire C, Zanetta S, Alfonsi M, Janoray G, Chatellier T, Garcia-Ramirez M, Gherga E, Hammoud Y, Burgy M, Etienne-Selloum N, Pechery A, Girard-Calais MH, Velten M, Pignon JP, Wanneveich M, Bourhis J. Borel C, et al. Among authors: velten m. Radiother Oncol. 2024 May 19;197:110329. doi: 10.1016/j.radonc.2024.110329. Online ahead of print. Radiother Oncol. 2024. PMID: 38768714 Free article.
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.
Connolly SJ, Sharma M, Cohen AT, Demchuk AM, Członkowska A, Lindgren AG, Molina CA, Bereczki D, Toni D, Seiffge DJ, Tanne D, Sandset EC, Tsivgoulis G, Christensen H, Beyer-Westendorf J, Coutinho JM, Crowther M, Verhamme P, Amarenco P, Roine RO, Mikulik R, Lemmens R, Veltkamp R, Middeldorp S, Robinson TG, Milling TJ Jr, Tedim-Cruz V, Lang W, Himmelmann A, Ladenvall P, Knutsson M, Ekholm E, Law A, Taylor A, Karyakina T, Xu L, Tsiplova K, Poli S, Kallmünzer B, Gumbinger C, Shoamanesh A; ANNEXA-I Investigators. Connolly SJ, et al. N Engl J Med. 2024 May 16;390(19):1745-1755. doi: 10.1056/NEJMoa2313040. N Engl J Med. 2024. PMID: 38749032 Clinical Trial.
Long-term survival for lymphoid neoplasms and national health expenditure (EUROCARE-6): a retrospective, population-based study.
Sant M, Vener C, Lillini R, Rossi S, Bonfarnuzzo S, Marcos-Gragera R, Maynadié M, Innos K, Paapsi K, Visser O, Bernasconi A, Demuru E, Di Benedetto C, Mousavi SM, Blum M, Went P, Serraino D, Bennett D, Sánchez MJ, De Angelis R; EUROCARE-6 Working Group. Sant M, et al. Lancet Oncol. 2024 Jun;25(6):731-743. doi: 10.1016/S1470-2045(24)00141-4. Epub 2024 May 1. Lancet Oncol. 2024. PMID: 38703784
Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based study.
De Angelis R, Demuru E, Baili P, Troussard X, Katalinic A, Chirlaque Lopez MD, Innos K, Santaquilani M, Blum M, Ventura L, Paapsi K, Galasso R, Guevara M, Randi G, Bettio M, Botta L, Guzzinati S, Dal Maso L, Rossi S; EUROCARE-6 Working Group. De Angelis R, et al. Lancet Oncol. 2024 Mar;25(3):293-307. doi: 10.1016/S1470-2045(23)00646-0. Epub 2024 Jan 30. Lancet Oncol. 2024. PMID: 38307102
396 results